Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266

被引:18
作者
Gadó, K
Pállinger, É
Kovács, P
Takács, E
Szilvási, I
Tóth, BE
Nagy, G
Domján, G
Falus, A
机构
[1] Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1089 Budapest, Hungary
[2] Natl Inst Haematol & Immunol, Budapest, Hungary
[3] Semmelweis Univ, Kutvolgyi Clin Unit, Isotope Lab, H-1089 Budapest, Hungary
[4] Semmelweis Univ, Fac Med, Dept Human Morphol & Dev Biol, Neuroendocrine Res Lab, Budapest, Hungary
[5] Semmelweis Univ, Fac Hlth Sci, Dept Med & Geriatry, Budapest, Hungary
关键词
prolactin; myeloma; proliferation; apoptosis;
D O I
10.1016/S0165-2478(02)00008-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In certain types of solid tumours and lymphomas prolactin (PRL) potentiates tumour cell proliferation and exerts anti-apoptotic effect, Tumour cells themselves can produce PRL and express PRL-receptors. Hyperprolactinemia is associated with different tumours, also. Multiple myeloma (MM) is a haematological malignancy caused by the clonal expansion of terminally differentiated plasma cells in the bone marrow. Recently. we demonstrated PRL immunostaining in bone marrow, cells of MM patients and art elevated level of serum PRL of MM patients with advanced disease. In the present study, we tested the effect of PRL on a U266 human myeloma cell line and demonstrated constitutive and melphalan-stimulated intracytoplasmic PRL in U266 cells. Exogeneous PRL inhibited the proliferation and immunoglobulin (Ig) production of U266 myeloma cells. Concerning etoposide-induced apoptosis. PRL had a double-faceted effect depending on the applied dose: high, pharmacological doses (corresponding to hyperprolactinemia), inhibited apoptosis. whereas near physiological doses exerted a pro-apoptotic effect. These data indicate a definite effect of PRL on a human myeloma cell line. We demonstrated a direct inhibition of PRL on tumour cell growth, while its reciprocal effect on apoptosis refers to an important regulatory role of PRL. 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 32 条
[1]  
AAGAARDTILLERY KM, 1995, J IMMUNOL, V155, P3297
[2]  
Anderson KC, 1999, SEMIN HEMATOL, V36, P14
[3]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[4]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[5]   INDEPENDENT AND SYNERGISTIC EFFECT OF INTERLEUKIN-2 AND PROLACTIN ON DEVELOPMENT OF T-DERIVED AND NK-DERIVED LAK EFFECTORS [J].
CESANO, A ;
OBERHOLTZER, E ;
CONTARINI, M ;
GEUNA, M ;
BELLONE, G ;
MATERA, L .
IMMUNOPHARMACOLOGY, 1994, 28 (01) :67-75
[6]   AUTOCRINE STIMULATION OF NB2 CELL-PROLIFERATION BY SECRETED, BUT NOT INTRACELLULAR, PROLACTIN [J].
DAVIS, JA ;
LINZER, DIH .
MOLECULAR ENDOCRINOLOGY, 1988, 2 (08) :740-746
[7]   A HUMAN-B-LYMPHOBLASTOID CELL-LINE PRODUCES PROLACTIN [J].
DIMATTIA, GE ;
GELLERSEN, B ;
BOHNET, HG ;
FRIESEN, HG .
ENDOCRINOLOGY, 1988, 122 (06) :2508-2517
[8]   Elevated levels of serum prolactin in patients with advanced multiple myeloma [J].
Gadó, K ;
Rimanóczi, E ;
Hasitz, A ;
Gigler, G ;
Tóth, BE ;
Nagy, GM ;
Pálóczi, K ;
Domján, G .
NEUROIMMUNOMODULATION, 2001, 9 (04) :231-236
[9]   Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients [J].
Gadó, K ;
Nagy, G ;
Hasitz, A ;
Tóth, BE ;
Rimanóczi, E ;
Domján, G .
NEUROIMMUNOMODULATION, 2001, 9 (02) :95-102
[10]  
GADO K, CELL BIOL INT, V24, P195